The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum

Antimicrob Agents Chemother. 2011 Mar;55(3):1300-4. doi: 10.1128/AAC.01103-10. Epub 2010 Dec 28.

Abstract

Plasmodium species ex vivo sensitivity assay protocols differ in the requirement for leukocyte removal before culturing. This study shows that the presence of leukocytes significantly increases the 50% inhibitory concentration (IC₅₀) of P. vivax and P. falciparum to artesunate and chloroquine relative to results with the paired leukocyte-free treatment. Although leukocyte removal is not an essential requirement for the conduct of ex vivo assays, its use has important implications for the interpretation of temporal and spatial antimalarial sensitivity data.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / pharmacology*
  • Artemisinins / pharmacology*
  • Artesunate
  • Chloroquine / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Leukocytes / physiology*
  • Parasitic Sensitivity Tests
  • Plasmodium falciparum / drug effects*
  • Plasmodium vivax / drug effects*

Substances

  • Antimalarials
  • Artemisinins
  • Artesunate
  • Chloroquine